

Data Sharing Statement

Article Info	https://dx.doi.org/10.21037/jtd-23-1388	
Item	Question	Authors' Response (place "-" if not applicable)
1	Would you like to share data collected for your study to others?	Yes.
2	If not, would you like to share the reason for your decision?	-
3	What data in particular will be shared?	The patient characteristics and the efficacy and safety of sintilimab combined with paclitaxel and platinum for locally advanced resectable ESCC can be particularly shared.
4	Any other documents will be share? Such as study protocol, statistical analysis plan, informed consent form, clinical study report, analytic code.	All data can be shared if requested.
5	When will data availability begin?	From the publication date.
6	When will data availability end?	Two years within the publication date, since the technique or survival data may be updated over time.
7	To whom will you share the data?	Medical doctors who are interested in this study.
8	For what type of analysis or purpose?	For analysis to evaluate the efficacy and safety of PD-L1 inhibitors in ESCC patients.
9	How or where can the data/documents be obtained?	Emails could be sent to the address below to obtain the shared data: dr.leebin@outlook.com.
10	Any other restrictions?	We may balance the potential benefits and risks for each request and then provide the data that could be shared.